Moderna, Inc. (MRNA)
| Market Cap | 20.74B +59.8% |
| Revenue (ttm) | 1.94B -39.9% |
| Net Income | -2.82B |
| EPS | -7.25 |
| Shares Out | 394.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,482,476 |
| Open | 52.22 |
| Previous Close | 53.83 |
| Day's Range | 49.22 - 52.77 |
| 52-Week Range | 22.28 - 59.55 |
| Beta | 1.35 |
| Analysts | Hold |
| Price Target | 33.00 (-37.17%) |
| Earnings Date | Feb 13, 2026 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $33.0, which is a decrease of -37.17% from the latest price.
News
FDA reversals leave investors worrying about the fates of other experimental drugs
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing co...
The Sun Will Shine On Moderna Again - Initiating With A Buy
Moderna is initiated at a buy rating, as multiyear growth drivers and robust 2026 guidance signal a turnaround. mNEXSPIKE approvals, flu and combo vaccines, and mRNA therapeutics expansion underpin Mo...
Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom
Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP tec...
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang
Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and a...
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
Moderna Inc. (NASDAQ: MRNA) shares are up during Wednesday's premarket session following a settlement agreement with Arbutus Biopharma Corporation (NASDAQ: ABUS) and Roivant Inc.'s (NASDAQ: ROIV) Gene...
Moderna Stock Rallies. This Big Risk Just Got Eliminated.
The company settles to resove patent litigation related to its Covid-19 vaccine, removing an overhang for shares.
Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline
The deal would provide ‘certainty' for Moderna's vaccine portfolio.
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor.
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences , and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its ...
Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026 District Court's Section 1498 decision to be appealed to the Federal Cir...
Moderna's Covid-Flu Vaccine Recommended for Approval in EU
The recommendation from regulators paves the way for the shot's approval in the European Union at a time the company is facing scrutiny in the U.S.
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive ...
Moderna gets EU regulator nod for combined COVID, flu vaccine
Europe's medicines regulator on Friday recommended granting marketing authorisation to mCombriax, making Moderna's messenger RNA vaccine the world's first combined shot for people aged 50 and older ag...
Moderna Stock: How Far Can The Flu Shot Fly?
Moderna (MRNA) – a developer of mRNA-focused therapeutics and vaccines – has recorded a 6-day winning streak, accumulating gains of 25% during this time. The company's market capitalization has increa...
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost
U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it changed course and agreed to review a Moderna flu vaccin...
BioNTech sues Moderna for patent infringement over COVID-19 shots
Biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 vaccine mNexspike infringes a patent related to BioNTech and Pfizer's competing ...
Moderna to Present at Upcoming Conferences in March 2026
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 46th Annual Hea...
FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars
The stock's movement comes after the U.S. Food and Drug Administration (FDA) notified Moderna that its biologics license application for mRNA-1010 will proceed to review, adding pressure as broader ma...
FDA agrees to review Moderna's mRNA flu vaccine application in a reversal
Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a decisi...
Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine
The FDA's “refuse-to-file” letter sent to reject Moderna's application is a rarity: A 2021 study found that 4% of the nearly 2,500 applications submitted to the agency receive such letters, many of wh...
Moderna got the FDA to change its mind and review its flu vaccine after some concessions
Moderna's stock was surging after the FDA said it would review the biotech's flu-vaccine candidate, a week after it had refused to do so.
FDA reverses decision not to review Moderna's new flu vaccine
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.